Sanofi

Principia Biopharma to Hold Virtual Analyst Event to Discuss BTK Inhibition: Beyond B Cells and Antibodies

Wednesday, June 3, 2020 - 9:01pm

The webcast replay will be available after the conclusion of the presentation.

Key Points: 
  • The webcast replay will be available after the conclusion of the presentation.
  • Principia is a late-stage biopharmaceutical company dedicated to bringing transformative therapies to patients with significant unmet medical needs in immune-mediated diseases.
  • This highly reproducible approach enables the company to pursue multiple programs efficiently, having discovered three drug candidates.
  • PRN2246/SAR442168 is a covalent BTK inhibitor which crosses the blood-brain barrier and is partnered with Sanofi.

Sanofi to launch “Action 2020”, a worldwide employee stock purchase plan

Wednesday, June 3, 2020 - 5:00pm

PARIS June 3, 2020 Sanofi announces the launch of Action 2020 on June 8, 2020, a worldwide stock purchase plan reserved for its employees, which should take place in almost 75 countries.

Key Points: 
  • PARIS June 3, 2020 Sanofi announces the launch of Action 2020 on June 8, 2020, a worldwide stock purchase plan reserved for its employees, which should take place in almost 75 countries.
  • On February 5, 2020 the Board of Directors authorized an issuance of ordinary shares of Sanofi for the benefit of employees participating in the Group Savings Plan.
  • Any subscription per five shares as part of such issuance shall entitle the employee to one matching share.
  • This press release does not constitute an offer to sell or a solicitation to purchase Sanofi shares.

Sanofi to present oncology strategy, provide update on portfolio and emerging pipeline

Tuesday, June 2, 2020 - 6:00am

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended.

Key Points: 
  • This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended.
  • Forward-looking statements are generally identified by the words expects, anticipates, believes, intends, estimates, plans and similar expressions.
  • This situation is changing rapidly and additional impacts may arise of which we are not currently aware and may exacerbate other previously identified risks.
  • Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Idiopathic Intracranial Hypertension Therapeutics Market 2019-2023 | Rising Incidences Of Idiopathic Intracranial Hypertension to Boost Growth | Technavio

Monday, June 1, 2020 - 9:00pm

Our idiopathic intracranial hypertension therapeutics market report covers the following areas:

Key Points: 
  • Our idiopathic intracranial hypertension therapeutics market report covers the following areas:
    This study identifies an increasing number of awareness campaigns as one of the prime reasons driving the idiopathic intracranial hypertension therapeutics market growth during the next few years.
  • Idiopathic Intracranial Hypertension Therapeutics Market 2019-2023: Vendor Analysis
    We provide a detailed analysis of around 25 vendors operating in the Idiopathic Intracranial Hypertension Therapeutics Market, including some of the vendors such as AbbVie Inc., Astellas Pharma Inc., Cadila Healthcare Ltd., Johnson & Johnson Services Inc., Merck & Co. Inc., Mylan NV, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.
  • Backed with competitive intelligence and benchmarking, our research reports on the Idiopathic Intracranial Hypertension Therapeutics Market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.
  • Idiopathic Intracranial Hypertension Therapeutics Market 2019-2023: Key Highlights

Zentiva Expands Production Capacity by Completing Acquisition of Ankleshwar Manufacturing Site

Monday, June 1, 2020 - 8:00am

PRAGUE, June 1, 2020 /PRNewswire/ -- Zentiva Group announces the completion of its acquisition of a manufacturing site in Ankleshwar, India, from Sanofi.

Key Points: 
  • PRAGUE, June 1, 2020 /PRNewswire/ -- Zentiva Group announces the completion of its acquisition of a manufacturing site in Ankleshwar, India, from Sanofi.
  • We are continuing to deliver strong growth at Zentiva and the completion of this acquisition is an important milestone for our company," said Nick Haggar, Chief Executive Officer of Zentiva.
  • "I am so proud that our Ankleshwar team will be part of an even stronger Zentiva, integrated into the organization's long-term growth strategy,"added Ashwani Sood, Head of the Ankleshwar site.
  • Established in 1987, the Ankleshwar manufacturing site has a chemistry and biotechnology development center, and manufactures both intermediates and pharmaceutical formulations.

Sanofi announces closing of Regeneron stock sale

Friday, May 29, 2020 - 9:01pm

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended.

Key Points: 
  • This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended.
  • Forward-looking statements are generally identified by the words expects, anticipates, believes, intends, estimates, plans and similar expressions.
  • Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.
  • The proposed public offering may not be successful, and even if it is, we may not achieve the anticipated benefits thereof.

Mylan Invalidates Sanofi's Lantus® SoloSTAR® Device Patents in IPR Proceedings

Friday, May 29, 2020 - 8:24pm

HERTFORDSHIRE, England and PITTSBURGH, May 29, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced that the U.S. Patent and Trademark Appeal Board (PTAB) has ruled in favor of Mylan in inter partes review (IPR) proceedings finding all challenged claims of Sanofi's Lantus SoloSTAR device patents, U.S. Patent Nos.

Key Points: 
  • HERTFORDSHIRE, England and PITTSBURGH, May 29, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced that the U.S. Patent and Trademark Appeal Board (PTAB) has ruled in favor of Mylan in inter partes review (IPR) proceedings finding all challenged claims of Sanofi's Lantus SoloSTAR device patents, U.S. Patent Nos.
  • Last month, the PTAB invalidated the sole challenged claim of another Lantus SoloSTAR device patent, U.S. Patent No.
  • The '844 and '652 patents are the only remaining patents asserted by Sanofi against Mylan's insulin glargine products.
  • Sanofi's total IQVIA sales for the 12 months ending March 31, 2020, were approximately $1.71 billion for Lantus 100 Units/mL and about $4.32 billion for Lantus SoloSTAR.

Ocular Therapeutix™ to Present at the Jefferies Virtual Healthcare Conference

Friday, May 29, 2020 - 1:00pm

Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Antony Mattessich, President and Chief Executive Officer of Ocular Therapeutix, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 2:30 PM EDT.

Key Points: 
  • Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Antony Mattessich, President and Chief Executive Officer of Ocular Therapeutix, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 2:30 PM EDT.
  • Investors participating in the conference who are interested in meeting with Ocular Therapeutix management should contact their Jefferies representative.
  • Ocular Therapeutixs first commercial drug product, DEXTENZA (dexamethasone ophthalmic insert), is FDA-approved for the treatment of ocular inflammation and pain following ophthalmic surgery.
  • Also, in collaboration with Regeneron, Ocular Therapeutix is currently developing on OTX-IVT (aflibercept suprachoroidal injection), an extended-delivery formulation of aflibercept for the treatment of retinal diseases.

Libtayo® (cemiplimab-rwlc) longer-term results in advanced cutaneous squamous cell carcinoma presented at ASCO 2020 show durable responses that deepen over time

Friday, May 29, 2020 - 1:00pm

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended.

Key Points: 
  • This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended.
  • Forward-looking statements are generally identified by the words expects, anticipates, believes, intends, estimates, plans and similar expressions.
  • Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.
  • Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (http://newsroom.regeneron.com) and its Twitter feed ( http://twitter.com/regeneron ).

Sanofi names new leaders to Executive Committee

Friday, May 29, 2020 - 6:00am

PARIS May 29, 2020 - Sanofi has named four new leaders to its Executive Committee.

Key Points: 
  • PARIS May 29, 2020 - Sanofi has named four new leaders to its Executive Committee.
  • The complete Sanofi Executive Committee now includes the four heads of the Companys global business units (Sanofi Genzyme, Sanofi Pasteur, General Medicines, and Consumer Healthcare) as well as the global Heads of Research and Development, Industrial Affairs, Finance, Human Resources, Legal and Digital.
  • We need leaders who come to Sanofi with a fresh perspective as well as leaders who have grown up within the company, says Paul Hudson, Chief Executive Officer at Sanofi.
  • Thomas Triomphe currently serves as Head of Franchises and Product Strategy for Sanofi Pasteur, and will be promoted to Executive Vice President, Head of Sanofi Pasteur, effective June 15.